Peter Mohr

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

Eliezer M. Van Allen, Diana Miao, Bastian Schilling et al. · Science · 2015 · 2.9K citations · Full text

Immune Evasion, Cancer Immunosurveillance, Immune Checkpoint Activity +14

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

Jeffrey S. Weber, Sandra P. D’Angelo, David R. Minor et al. · The Lancet Oncology · 2015 · 2.6K citations

Checkmate 037, Medicine, Melanoma +9

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

Keith T. Flaherty, Caroline Robert, Peter Hersey et al. · New England Journal of Medicine · 2012 · 2.1K citations · Full text

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas et al. · New England Journal of Medicine · 2014 · 1.8K citations · Full text

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas et al. · The Lancet · 2015 · 1.4K citations

Versus Dabrafenib, Val600 Braf-mutant Melanoma, Oncology +7